logo dha

DHA

10/03/2025
08:00
Horário oficial: Brasília

10/03/2025
Cardiologia
Português
logo dha

Seguindo

Sobre este conteúdo

Mini Review
Special issue: Renal denervation: Evidence and challenges in clinical practice.
Published: 11 April 2024
Impact of renal denervation on quality of life (How does renal denervation contribute to improving hypertension treatment affected by poor medication adherence?)

Keisuke Okamura,
Hideaki Shimada,
Keisuke Imazato,
Hideto Sako,
Akihiro Udo,
Kenichiro Taniguchi,
Shogo Morisaki,
Ichiro Imamura,
Hidenori Urata,
Hisatomi Arima &
Shin-ichiro Miura
Hypertension Research volume 47, pages2652–2658 (2024)Cite this article

 

 

Abstract

The US Food and Drug Administration has approved renal denervation (RDN) as a new treatment option for hypertension (HT) because it not only has antihypertensive effects but also improves the quality of blood pressure (BP) reduction. RDN is expected to be increasingly used in clinical practice in the future. This review summarizes the impact of RDN on quality of life (QOL). Although the treatment of HT aims to improve life prognosis, the use of antihypertensive agents can impair QOL because of adverse effects and lifestyle changes associated with long-term medication use. Consequently, poor adherence to antihypertensive agents is a common problem and may be the most important issue affecting patient QOL. In RDN trials in patients taking antihypertensive agents, approximately 40% of patients had poor adherence to the drugs. Poor adherence is often the cause of resistant hypertension. Therefore, RDN should be well suited to treating HT and improving QOL. Studies have shown that approximately 30% of HT patients prefer RDN to drug treatment. Patients who prefer RDN are typically male and younger and have high BP, poor adherence, and a history of adverse effects of antihypertensive agents. We hope that RDN will improve not only life prognosis but also QOL in HT patients because of its benefits for adherence. Furthermore, we expect that in the future, RDN will be used in other sympathetic nervous system-related diseases, such as heart failure, atrial fibrillation, and sleep apnea syndrome.

 

Mini Review
Special issue: Renal denervation: Evidence and challenges in clinical practice.
Published: 11 April 2024
Impact of renal denervation on quality of life (How does renal denervation contribute to improving hypertension treatment affected by poor medication adherence?)

Keisuke Okamura,
Hideaki Shimada,
Keisuke Imazato,
Hideto Sako,
Akihiro Udo,
Kenichiro Taniguchi,
Shogo Morisaki,
Ichiro Imamura,
Hidenori Urata,
Hisatomi Arima &
Shin-ichiro Miura
Hypertension Research volume 47, pages2652–2658 (2024)Cite this article

 

 

Abstract

The US Food and Drug Administration has approved renal denervation (RDN) as a new treatment option for hypertension (HT) because it not only has antihypertensive effects but also improves the quality of blood pressure (BP) reduction. RDN is expected to be increasingly used in clinical practice in the future. This review summarizes the impact of RDN on quality of life (QOL). Although the treatment of HT aims to improve life prognosis, the use of antihypertensive agents can impair QOL because of adverse effects and lifestyle changes associated with long-term medication use. Consequently, poor adherence to antihypertensive agents is a common problem and may be the most important issue affecting patient QOL. In RDN trials in patients taking antihypertensive agents, approximately 40% of patients had poor adherence to the drugs. Poor adherence is often the cause of resistant hypertension. Therefore, RDN should be well suited to treating HT and improving QOL. Studies have shown that approximately 30% of HT patients prefer RDN to drug treatment. Patients who prefer RDN are typically male and younger and have high BP, poor adherence, and a history of adverse effects of antihypertensive agents. We hope that RDN will improve not only life prognosis but also QOL in HT patients because of its benefits for adherence. Furthermore, we expect that in the future, RDN will be used in other sympathetic nervous system-related diseases, such as heart failure, atrial fibrillation, and sleep apnea syndrome.

 

Comentários

Deixe um comentário

19 Aulas
30 Horas

SBC

7 Aulas
15 Horas

Comentários

Deixe um comentário

Thumb
Íntegra
20/03/2023
Socaba-06.07
01:40:05
Íntegra
06/07/2023
Kit_Mkt_Cianotica-Thumb-Podcast
02:16:48
Podcast
20/09/2024
Screenshot_2
18:45
Corte
05/07/2021
Thumb (68)
01:14:37

SMC

Vídeo
07/06/2024
Screenshot_1
01:46:16
Íntegra
02/07/2025
Captura De Tela 2023-09-19 145002
1:07:05
Íntegra
18/09/2023
Thumb
01:06:04
Íntegra
18/08/2025
Sem Título
14:11
Corte
22/04/2024
[Escola De Eco] Eco De Excelência – Ep. 15 – Corte Apical 5 Câmaras
Íntegra
18/07/2020
Socerj Thumb
25:07
Íntegra
14/08/2023
Kit_Webinar_Socaba_Thumbnail_Podcast
Podcast
04/08/2023
Kit-Mkt-Sotierjthumb-Podcast
32:19
Podcast
14/08/2025
Choque Cardiogênico: Quando Indicar E Qual O Melhor Suporte De Assistência Ventricular?
20:47
Corte
06/05/2022
Thumb Sbc Pr
Íntegra
25/05/2021
Carrinho de compras